2024 Off to a Strong Start With Clean 1Q Beat, Reasons for Optimism on Reaffirmed Guide
⬆ $Myriad Genetics(MYGN)$ - We reiterate our Outperform rating on shares of Myriad Genetics after a 4% top-line beat and EBITDA of $4.0M vs. the $(6.5)M consensus. We view...
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/2024-off-to-a-strong-start-with-clean-1q-beat-reasons-for-optimism-on-reaffirmed-guide?utm_source=tiger_community
By CGS CIMB Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/cgs-cimb-research?utm_source=tiger_community
On Myriad Genetics (MYGN):- https://www.smartkarma.com/entities/myriad-genetics-inc?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
